The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Fractalkine Is a Novel Human Adipochemokine Associated With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: Leukocyte infiltration of adipose is a critical determinant of obesity-related metabolic diseases. Fractalkine (CX3CL1) and its receptor (CX3CR1) comprise a chemokine system involved in leukocyte recruitment and adhesion in atherosclerosis, but its role in adipose inflammation and type 2 diabetes is unknown. RESEARCH DESIGN AND METHODS: CX3CL1 mRNA and protein were quantified in subcutaneous adipose and blood during experimental human endotoxemia and in lean and obese human adipose. CX3CL1 cellular source was probed in human adipocytes, monocytes, and macrophages, and CX3CL1-blocking antibodies were used to assess its role in monocyte-adipocyte adhesion. The association of genetic variation in CX3CR1 with metabolic traits was determined in a community-based sample. Finally, plasma CX3CL1 levels were measured in a case-control study of type 2 diabetes. RESULTS: Endotoxemia induced adipose CX3CL1 mRNA (32.7-fold, P < 1 × 10−5) and protein (43-fold, P = 0.006). Obese subjects had higher CX3CL1 levels in subcutaneous adipose compared with lean (0.420 ± 0.387 vs. 0.228 ± 0.187 ng/mL, P = 0.04). CX3CL1 was expressed and secreted by human adipocytes and stromal vascular cells. Inflammatory cytokine induction of CX3CL1 in human adipocytes (27.5-fold mRNA and threefold protein) was completely attenuated by pretreatment with a peroxisome proliferator–activated receptor-γ agonist. A putative functional nonsynonymous single nucleotide polymorphism (rs3732378) in CX3CR1 was associated with adipose and metabolic traits, and plasma CX3CL1 levels were increased in patients with type 2 diabetes vs. nondiabetics (0.506 ± 0.262 vs. 0.422 ± 0.210 ng/mL, P < 0.0001). CONCLUSIONS: CX3CL1-CX3CR1 is a novel inflammatory adipose chemokine system that modulates monocyte adhesion to adipocytes and is associated with obesity, insulin resistance, and type 2 diabetes. These data provide support for CX3CL1 as a diagnostic and therapeutic target in cardiometabolic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632
A new class of membrane-bound chemokine with a CX3C motif
Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., & Schall, T. J. (1997) · Nature · doi:10.1038/385640a0 · Cited by 2,013
Ghanim, H., Abuaysheh, S., Sia, C. L., Korzeniewski, K., Chaudhuri, A., Fernandez-Real, J. M., & Dandona, P. (2009) · Diabetes Care · doi:10.2337/dc09-0979 · Cited by 494
Decreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis
Lesnik, P., Haskell, C. A., & Charo, I. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15555 · Cited by 487
Inouye, K. E., Shi, H., Howard, J. K., Daly, C. H., Lord, G. M., Rollins, B. J., & Flier, J. S. (2007) · Diabetes · doi:10.2337/db07-0425 · Cited by 252 · cited 1×
“However, adverse metabolic consequences are only partially attenuated in CCL2- or CCR2-deficient mice, suggesting involvement of additional chemokine pathways (6).”
BackgroundD'Haese, J. G., Demir, I. E., Friess, H., & Ceyhan, G. O. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903540265 · Cited by 116
Cited by
Adipose tissue inflammation and metabolic dysfunction in obesity
Kawai, T., Autieri, M. V., & Scalia, R. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00379.2020 · Cited by 1,947
The cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551
Adipokine dysregulation and adipose tissue inflammation in human obesity
Unamuno, X., Gómez‐Ambrosi, J., Rodríguez, A., Becerril, S., Frühbeck, G., & Catalán, V. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12997 · Cited by 610
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Role of innate and adaptive immunity in obesity-associated metabolic disease
McLaughlin, T., Ackerman, S. E., Shen, L., & Engleman, E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88876 · Cited by 444
Metadata
- Authors
- Shah, R., Hinkle, C. C., Ferguson, J. F., Mehta, N. N., Li, M., Qu, L., Lu, Y., Putt, M. E., Ahima, R. S., & Reilly, M. P.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1512-1518
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2110335402
- Cited by
- 169
- References
- 7
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fractalkine Is a Novel Human Adipochemokine Associated With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/db10-0956
- The paper
- Shah, R., Hinkle, C. C., Ferguson, J. F., Mehta, N. N., Li, M., Qu, L., Lu, Y., Putt, M. E., Ahima, R. S., & Reilly, M. P. (2011). Fractalkine Is a Novel Human Adipochemokine Associated With Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db10-0956
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.